Jazz advances portfolio with first I-O transaction

7 April 2022
jazzpharma_big

Ireland-headquartered Jazz Pharmaceuticals (Nasdaq: JAZZ) has entered into a licensing agreement under which it has acquired exclusive global development and commercialization rights to Werewolf Therapeutics’ (Nasdaq: HOWL) investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) Indukine molecule.

WTX-613 expands Jazz's robust oncology pipeline and represents first immuno-oncology program in company's R&D portfolio, the company noted.

News of the deal propelled Werewolf’s shares up almost 43% to $6.75, while Jazz edged up1.1% to $165.00. Werewolf joined the Nasdaq in April last year, via a $120 million initial public offering.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology